Loxo Oncology Stock Fundamentals
Loxo Oncology fundamentals help investors to digest information that contributes to Loxo Oncology's financial success or failures. It also enables traders to predict the movement of Loxo Stock. The fundamental analysis module provides a way to measure Loxo Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Loxo Oncology stock.
Loxo |
Loxo Oncology Company Return On Asset Analysis
Loxo Oncology's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Loxo Oncology Return On Asset | -0.0059 |
Most of Loxo Oncology's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Loxo Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Loxo Oncology has a Return On Asset of -0.0059. This is 99.93% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 95.79% lower than that of the firm.
Loxo Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Loxo Oncology's current stock value. Our valuation model uses many indicators to compare Loxo Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Loxo Oncology competition to find correlations between indicators driving Loxo Oncology's intrinsic value. More Info.Loxo Oncology is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Loxo Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Loxo Oncology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Loxo Oncology's earnings, one of the primary drivers of an investment's value.Loxo Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Loxo Oncology's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Loxo Oncology could also be used in its relative valuation, which is a method of valuing Loxo Oncology by comparing valuation metrics of similar companies.Loxo Oncology is currently under evaluation in return on asset category among related companies.
Loxo Fundamentals
Return On Equity | -0.63 | |||
Return On Asset | -0.0059 | |||
Profit Margin | (43.49) % | |||
Operating Margin | (50.33) % | |||
Current Valuation | 6.56 B | |||
Shares Outstanding | 30.75 M | |||
Shares Owned By Insiders | 3.70 % | |||
Shares Owned By Institutions | 92.93 % | |||
Number Of Shares Shorted | 1.03 M | |||
Price To Earning | (20.33) X | |||
Price To Book | 18.92 X | |||
Price To Sales | 49.84 X | |||
Revenue | 144.8 M | |||
Gross Profit | (118.74 M) | |||
EBITDA | (147.98 M) | |||
Net Income | (62.98 M) | |||
Cash And Equivalents | 622 M | |||
Cash Per Share | 3.71 X | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 3.62 X | |||
Book Value Per Share | 12.50 X | |||
Cash Flow From Operations | 234.3 M | |||
Short Ratio | 0.50 X | |||
Earnings Per Share | (2.09) X | |||
Price To Earnings To Growth | (2.75) X | |||
Number Of Employees | 59 | |||
Beta | 2.97 | |||
Market Capitalization | 7.22 B | |||
Total Asset | 157.46 M | |||
Retained Earnings | (82.93 M) | |||
Working Capital | 153.79 M | |||
Current Asset | 156.64 M | |||
Current Liabilities | 2.85 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Loxo Stock
If you are still planning to invest in Loxo Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Loxo Oncology's history and understand the potential risks before investing.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |